



## Pennsylvania Pregnancy Wellness Collaborative

May 28, 2025

### Dear Honorable Sir or Madam:

I am writing on behalf of the Pennsylvania Pregnancy Wellness Collaborative (PPWC) to share our serious concerns regarding the findings of two recent studies published by the Ethics and Public Policy Center, which analyzed 865,727 mifepristone abortions from 2017 to 2023. **The first reveals that 10.93% of women experienced serious adverse events**, including sepsis, infection, and hemorrhaging, within 45 days of taking the abortion pill, a rate over 22 times higher than previously reported in clinical trials.

Later, the same group **revealed Part 2 of the study**, finding that **more than one in 20 women needed a second abortion after the abortion pill failed to end their pregnancy**. Five percent of the women in the study had to pursue a repeat abortion within 45 days of taking the abortion pill mifepristone. This means that 11% of the time, a woman could suffer an adverse health event, and 5% of the time, the abortion pill is not effective.

We frequently hear that abortion is healthcare. The abortion pill has been championed by the abortion industry and labeled "safe and effective" since the FDA approved it 25 years ago. However, the data continues to show that the abortion pill is neither safe nor effective. We also know that here in Pennsylvania, hospitalizations after taking the abortion pill have tripled in the last 5 years. These findings underscore the urgent need for Pennsylvania lawmakers to take immediate action to protect women's health and safety.

PPWC calls upon the Pennsylvania General Assembly to:

- Reinstatement of In-Person Medical Evaluations: Require that mifepristone be prescribed only after a comprehensive, in-person medical evaluation to confirm gestational age and rule out ectopic pregnancies.
- Mandate Physician Oversight: Ensure that only licensed physicians prescribe and administer mifepristone, with the capability to manage potential complications.
- Implement Robust Reporting Requirements: Require healthcare providers to report all serious adverse events associated with mifepristone to state health authorities for monitoring and transparency.

PPWC is committed to advocating for policies that prioritize the well-being of women and families in Pennsylvania. We urge legislators to act swiftly to reinstate these critical safety measures.

Sincerely,

**The Board and Membership of the Pennsylvania Pregnancy Wellness Collaborative**



papregnancy.com



PO Box 7734, New Castle, PA 16107



info@papregnancy.com